Clean GH Release — No Side-Channel Activation
Most growth hormone secretagogues (GHRP-6, GHRP-2, hexarelin) stimulate GH release but also increase cortisol, prolactin, and ACTH — confounding variables that complicate research interpretation. Ipamorelin stands apart: published studies consistently show it stimulates GH release without significantly affecting cortisol, prolactin, or ACTH levels at GH-stimulating doses. This selectivity makes it a cleaner research tool for isolating GH pathway effects.
Key Takeaway
Ipamorelin is the most selective GH secretagogue studied — it raises growth hormone without elevating cortisol or prolactin, reducing confounding variables in research.
Mechanism of Action
Ipamorelin is a synthetic pentapeptide (Aib-His-D-2Nal-D-Phe-Lys-NH2) that mimics ghrelin at the GHS-R1a (growth hormone secretagogue receptor type 1a). This triggers intracellular calcium signaling cascades in pituitary somatotrophs, resulting in GH secretion. The mechanism is independent of GHRH pathways, which is why Ipamorelin and CJC-1295 DAC (a GHRH analog) are often studied together — they activate complementary receptor systems.
Dose-Response Profile
Clinical studies have mapped a clear dose-response relationship:
- GH onset: ~15-20 minutes post-administration
- Peak GH levels: ~40 minutes
- Return to baseline: 2-3 hours
- Selectivity confirmed: No significant cortisol or prolactin elevation across tested dose ranges
Research Applications
- GH pathway studies — Clean GH elevation for isolated pathway investigation
- Body composition research — GH effects on lean mass and adipose tissue
- Bone density — GH/IGF-1 axis effects on bone mineral density
- Sleep architecture — GH plays a key role in slow-wave sleep regulation
Available Products
Ipamorelin 5mg · 10mg. ≥98% HPLC verified with Certificate of Analysis.
For research purposes only. Not for human consumption.